The World Health Organization has asked wealthy nations to delay COVID-19 vaccine booster shots until low-income nations have a chance to vaccinate more people. The WHO’s goal is to vaccinate 10% of the population of each country by September. (CNBC Weekly)
CVS Health reported 12.3% higher revenue in the second quarter of 2021 due to its administration of some 17 million COVID-19 shots. The company also announced it will raise its minimum wage for workers to $15 an hour. (The Wall Street Journal)
In the wake of the Food and Drug Administration’s approval of Aduhelm, Biogen and Eisai are pushing to get their own Alzheimer’s therapy, lecanemab, cleared by the agency. “Under the breakthrough therapy designation from the FDA we have initiated communications with the FDA to seek the most optimal and expedited regulatory pathway forward for lecanemab,” said Eisai neurology chief Ivan Cheung. (Endpoints News)
Alzheimer’s patients remain in a “holding pattern,” with few having received Biogen’s Aduhelm even following its approval. That’s because doctors, hospitals and insurers remain conflicted about offering the controversial drug to patients. (STAT)
The U.S. reached its goal of getting one vaccine dose to 70% of the population, though one month later than expected. However, vaccination rates continue to stagnate. (Politico)
